Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06SBL
|
||||
| Former ID |
DIB010382
|
||||
| Drug Name |
MM-121
|
||||
| Synonyms |
SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Phase 2 | [1] | ||
| Company |
Merrimack pharmaceuticals; sanofi us
|
||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-3 | Target Info | Modulator | ||
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| Endocytosis | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | ||||
| ErbB receptor signaling network | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| WikiPathways | ErbB Signaling Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Signaling Pathways in Glioblastoma | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Heart Development | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01447706) A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.